Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Vesatolimod (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Mar 2019 Planned End Date changed from 1 Oct 2019 to 1 May 2019.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases